Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
The Journal of Investigative Dermatology
|
December 20, 2014
IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions
Angelo Massimiliano D'Erme, Dagmar Wilsmann-Theis, Julia Wagenpfeil, et al.
Cell Reports
|
December 16, 2020
The Proinflammatory Cytokine IL-36γ Is a Global Discriminator of Harmless Microbes and Invasive Pathogens within Epithelial Tissues
Thomas Macleod, Joseph S Ainscough, Christina Hesse, et al.
Experimental Dermatology
|
December 18, 2020
Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double-blind Phase Ib study
Alex Walker, Lars Erwig, Katie Foster, et al.
Lupus
|
May 5, 2025
The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis
Susan Manzi, Jorge Sánchez-Guerrero, Naoto Yokogawa, et al.
The Journal of Investigative Dermatology
|
August 19, 2007
Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis
Joerg Wenzel, Bettina Peters, Sabine Zahn, et al.
The Journal of Allergy and Clinical Immunology
|
October 13, 2006
Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis
Mark M Neis, Bettina Peters, Alexandra Dreuw, et al.
The Lancet. Rheumatology
|
May 10, 2026
Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial
Eric F Morand, Victoria P Werth, Joerg Wenzel, et al.
Lancet (London, England)
|
May 10, 2026
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial
Eric F Morand, Maria Dall'Era, Jorge Sanchez-Guerrero, et al.
American Journal of Human Genetics
|
February 9, 2006
Loss-of-function mutations in the keratin 5 gene lead to Dowling-Degos disease
Regina C Betz, Laura Planko, Sibylle Eigelshoven, et al.
International Journal of Cancer
|
September 5, 2008
Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin
Joerg Wenzel, Stefan Tomiuk, Sabine Zahn, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
The Journal of Investigative Dermatology
|
December 20, 2014
IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions
Angelo Massimiliano D'Erme, Dagmar Wilsmann-Theis, Julia Wagenpfeil, et al.
Cell Reports
|
December 16, 2020
The Proinflammatory Cytokine IL-36γ Is a Global Discriminator of Harmless Microbes and Invasive Pathogens within Epithelial Tissues
Thomas Macleod, Joseph S Ainscough, Christina Hesse, et al.
Experimental Dermatology
|
December 18, 2020
Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double-blind Phase Ib study
Alex Walker, Lars Erwig, Katie Foster, et al.
Lupus
|
May 5, 2025
The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis
Susan Manzi, Jorge Sánchez-Guerrero, Naoto Yokogawa, et al.
The Journal of Investigative Dermatology
|
August 19, 2007
Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis
Joerg Wenzel, Bettina Peters, Sabine Zahn, et al.
The Journal of Allergy and Clinical Immunology
|
October 13, 2006
Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis
Mark M Neis, Bettina Peters, Alexandra Dreuw, et al.
The Lancet. Rheumatology
|
May 10, 2026
Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial
Eric F Morand, Victoria P Werth, Joerg Wenzel, et al.
Lancet (London, England)
|
May 10, 2026
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial
Eric F Morand, Maria Dall'Era, Jorge Sanchez-Guerrero, et al.
American Journal of Human Genetics
|
February 9, 2006
Loss-of-function mutations in the keratin 5 gene lead to Dowling-Degos disease
Regina C Betz, Laura Planko, Sibylle Eigelshoven, et al.
International Journal of Cancer
|
September 5, 2008
Transcriptional profiling identifies an interferon-associated host immune response in invasive squamous cell carcinoma of the skin
Joerg Wenzel, Stefan Tomiuk, Sabine Zahn, et al.
Page
of 9